Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Dooley

Showing results (221-230 of 263) with videos related to

Pageof 27
Sort By:
The Journal of Antimicrobial Chemotherapy|June 9, 2022
Pharmacokinetics of standard versus high-dose isoniazid for treatment of multidrug-resistant tuberculosisKamunkhwala Gausi, Maxwell Chirehwa, Elisa H Ignatius, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|March 30, 2022
Performance of Xpert<sup>®</sup> MTB/RIF and Xpert<sup>®</sup> Ultra for the diagnosis of tuberculous meningitis in childrenN N Pradhan, M S Paradkar, A Kagal, et al.
International Journal of Cardiology. Cardiovascular Risk and Prevention|April 1, 2025
Social epidemiology of cardiometabolic risk factors in early adolescentsJason M Nagata, Christiane K Helmer, Jennifer H Wong, et al.
BMJ Open|December 31, 2024
Clinical predictors of 3-month isoniazid rifapentine (3HP)-related adverse drug reactions (ADR) during tuberculosis preventive therapy (PAnDoRA-3HP study): an observational study protocolChristine Sekaggya-Wiltshire, Irene Mbabazi, Ruth Mirembe Nabisere, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 29, 2021
Pharmacokinetics and Safety of 3 Months of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention in Pregnant WomenJyoti S Mathad, Rada Savic, Paula Britto, et al.
American Journal of Respiratory and Critical Care Medicine|March 8, 2022
Early Bactericidal Activity of Meropenem plus Clavulanate (with or without Rifampin) for Tuberculosis: The COMRADE Randomized, Phase 2A Clinical TrialVeronique De Jager, Nikhil Gupte, Silvia Nunes, et al.
American Journal of Respiratory and Critical Care Medicine|December 10, 2014
Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trialSusan E Dorman, Radojka M Savic, Stefan Goldberg, et al.
Child Protection and Practice|September 11, 2025
Examining the impact of early life adversity on adolescent sleep health: Findings from the ABCD studyEthan T Hunt, Keith Brazendale, Augusto César Ferreira De Moraes, et al.
American Journal of Respiratory and Critical Care Medicine|April 2, 2024
High-Dose Isoniazid Lacks EARLY Bactericidal Activity against Isoniazid-resistant Tuberculosis Mediated by katG Mutations: A Randomized Phase II Clinical TrialKamunkhwala Gausi, Elisa H Ignatius, Veronique De Jager, et al.
Plos One|May 10, 2016
A Phase 2 Randomized Trial of a Rifapentine plus Moxifloxacin-Based Regimen for Treatment of Pulmonary TuberculosisMarcus B Conde, Fernanda C Q Mello, Rafael Silva Duarte, et al.
Pageof 27

Showing results (221-230 of 263) with videos related to

Sort By:
Pageof 27
The Journal of Antimicrobial Chemotherapy|June 9, 2022
Pharmacokinetics of standard versus high-dose isoniazid for treatment of multidrug-resistant tuberculosisKamunkhwala Gausi, Maxwell Chirehwa, Elisa H Ignatius, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|March 30, 2022
Performance of Xpert<sup>®</sup> MTB/RIF and Xpert<sup>®</sup> Ultra for the diagnosis of tuberculous meningitis in childrenN N Pradhan, M S Paradkar, A Kagal, et al.
International Journal of Cardiology. Cardiovascular Risk and Prevention|April 1, 2025
Social epidemiology of cardiometabolic risk factors in early adolescentsJason M Nagata, Christiane K Helmer, Jennifer H Wong, et al.
BMJ Open|December 31, 2024
Clinical predictors of 3-month isoniazid rifapentine (3HP)-related adverse drug reactions (ADR) during tuberculosis preventive therapy (PAnDoRA-3HP study): an observational study protocolChristine Sekaggya-Wiltshire, Irene Mbabazi, Ruth Mirembe Nabisere, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 29, 2021
Pharmacokinetics and Safety of 3 Months of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention in Pregnant WomenJyoti S Mathad, Rada Savic, Paula Britto, et al.
American Journal of Respiratory and Critical Care Medicine|March 8, 2022
Early Bactericidal Activity of Meropenem plus Clavulanate (with or without Rifampin) for Tuberculosis: The COMRADE Randomized, Phase 2A Clinical TrialVeronique De Jager, Nikhil Gupte, Silvia Nunes, et al.
American Journal of Respiratory and Critical Care Medicine|December 10, 2014
Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trialSusan E Dorman, Radojka M Savic, Stefan Goldberg, et al.
Child Protection and Practice|September 11, 2025
Examining the impact of early life adversity on adolescent sleep health: Findings from the ABCD studyEthan T Hunt, Keith Brazendale, Augusto César Ferreira De Moraes, et al.
American Journal of Respiratory and Critical Care Medicine|April 2, 2024
High-Dose Isoniazid Lacks EARLY Bactericidal Activity against Isoniazid-resistant Tuberculosis Mediated by katG Mutations: A Randomized Phase II Clinical TrialKamunkhwala Gausi, Elisa H Ignatius, Veronique De Jager, et al.
Plos One|May 10, 2016
A Phase 2 Randomized Trial of a Rifapentine plus Moxifloxacin-Based Regimen for Treatment of Pulmonary TuberculosisMarcus B Conde, Fernanda C Q Mello, Rafael Silva Duarte, et al.
Pageof 27